Teva picks outsider to steer next growth phase
This article was originally published in Scrip
Teva Pharmaceutical Industries has opted for a company outsider to lead it to the next level in the company's development. Teva, which has seen its sales grow from $8.4 billion in 2006 to an anticipated $22 billion in 2012, has picked Dr Jeremy Levin to replace Shlomo Yanai as president and CEO of the Israeli company.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.